×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RNTX – rein therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RNTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/6
07:30 am
rntx
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Low
Report
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
11/3
06:10 pm
rntx
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
High
Report
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
11/3
05:03 pm
rntx
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
High
Report
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
11/3
07:30 am
rntx
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
10/9
08:01 am
rntx
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Low
Report
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
10/9
07:30 am
rntx
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
9/23
06:11 am
rntx
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Medium
Report
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
9/22
06:33 am
rntx
Rein Therapeutics (NASDAQ:RNTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Low
Report
Rein Therapeutics (NASDAQ:RNTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
05:31 pm
rntx
Form 4 Rein Therapeutics, Inc. For: Nov 14 Filed by: Cocke Travis W.
Low
Report
Form 4 Rein Therapeutics, Inc. For: Nov 14 Filed by: Cocke Travis W.
11/14
08:01 am
rntx
Form 10-Q Rein Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q Rein Therapeutics, Inc. For: Sep 30
11/3
07:45 am
rntx
Form 8-K Rein Therapeutics, Inc. For: Nov 03
High
Report
Form 8-K Rein Therapeutics, Inc. For: Nov 03
10/28
06:46 pm
rntx
Form 4 Rein Therapeutics, Inc. For: Oct 24 Filed by: Cocke Travis W.
High
Report
Form 4 Rein Therapeutics, Inc. For: Oct 24 Filed by: Cocke Travis W.
10/24
05:08 pm
rntx
Form 8-K Rein Therapeutics, Inc. For: Oct 23
Medium
Report
Form 8-K Rein Therapeutics, Inc. For: Oct 23
10/9
07:46 am
rntx
Form 8-K Rein Therapeutics, Inc. For: Oct 09
Low
Report
Form 8-K Rein Therapeutics, Inc. For: Oct 09
10/3
03:10 pm
rntx
Form 3 Rein Therapeutics, Inc. For: Sep 24 Filed by: Cocke Travis W.
Neutral
Report
Form 3 Rein Therapeutics, Inc. For: Sep 24 Filed by: Cocke Travis W.
9/26
06:47 pm
rntx
Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP
Medium
Report
Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: